Cancer Research and Biotechnology Ltd: A novel treatment CRB091 effectively reduces cancer cell proliferation in triple-negative breast cancer (TNBC)

ZUG, Switzerland, May 4, 2023 /PRNewswire/ -- CRB091, a novel drug candidate developed by Cancer Research and Biotechnology AG (CRB), has shown significant promise in reducing cancer cell proliferation

Related Keywords

United Kingdom ,Switzerland ,Sarah Haddad ,Kari Sarvanto ,Cancer Research ,Cancer Research Biotechnology ,Investigational New Drug ,Cancer ,Research ,Biotechnology ,Novel ,Treatment ,Rb091 ,Ffectively ,Educes ,Dancer ,Fell ,Proliferation ,Triple ,Negative ,Breast ,Nbc ,